Is Compounded Tirzepatide Going Away? What Actually Changed in October 2024

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 13 sources cited

Key Takeaways

• The FDA removed tirzepatide from its drug shortage list on October 2, 2024, ending the shortage-based pathway that had allowed broad compounding of tirzepatide
• Section 503A pharmacies can still legally compound tirzepatide for individual patients when the prescriber documents a specific clinical reason the commercial product cannot meet
• The narrower pathway is real, not panic-driven; the underlying federal statute that allows individualized compounding has existed since 1997
• A March 2025 federal court ruling affirmed the FDA's removal of tirzepatide from the shortage list, ending the legal challenge brought by the Outsourcing Facilities Association
• Patients currently on compounded tirzepatide should expect their prescribers to document clinical justification or transition them to brand Mounjaro or Zepbound depending on clinical fit

Direct answer

Not entirely. The FDA removed tirzepatide from its drug shortage list on October 2, 2024. That ended the broader compounding pathway that 503B outsourcing facilities and many 503A pharmacies had been using. Section 503A pharmacies can still compound tirzepatide for individual patients when a licensed prescriber documents a specific clinical reason the commercial Zepbound or Mounjaro product cannot be used. So "going away" is the wrong frame. The pathway narrowed; it did not close.

Table of contents

1. What the FDA actually did on October 2, 2024
2. The two-track compounding system: 503A vs 503B
3. What ended (and what survived)
4. The Outsourcing Facilities Association lawsuit and the March 2025 ruling
5. What "individualized clinical reason" actually means
6. The realistic patient pathway in 2026
7. Costs and access since the change
8. What FormBlends does differently now
9. The contrary view: should compounded tirzepatide go away entirely?
10. FAQ
11. Sources

What the FDA actually did on October 2, 2024

The FDA maintains a drug shortage list under Section 506C of the Federal Food, Drug, and Cosmetic Act. When a drug is on that list, both 503A and 503B compounders gain expanded authority to prepare compounded versions of that drug, including for patients who could otherwise use the commercial product. This is the legal mechanism that drove the compounded GLP-1 explosion from 2022 through 2024.

On October 2, 2024, the FDA published a determination that the tirzepatide shortage was resolved. Eli Lilly had expanded manufacturing capacity at its Concord, North Carolina facility and the Research Triangle Park location, and supply was meeting demand for both Mounjaro (the type 2 diabetes indication) and Zepbound (the obesity indication).

The agency's notice gave compounders a transition window. 503B outsourcing facilities had 60 days to wind down tirzepatide production. 503A pharmacies received a longer window because the law treats their patient-specific work differently. By early 2025, the shortage-based compounding pathway for tirzepatide was effectively closed.

The two-track compounding system: 503A vs 503B

Federal pharmacy law splits compounders into two categories, and the distinction matters here.

Feature	503A Pharmacy	503B Outsourcing Facility
Patient prescription required	Yes, patient-specific	No, can produce for office stock
Primary regulator	State board of pharmacy	FDA
Production volume	Smaller, individualized	Larger, batch
cGMP requirement	Not required (USP 797/795 standards apply)	Required (subset of cGMP)
Beyond-use date (BUD)	Shorter, per USP 797	Can be longer with stability data
Shortage compounding authority	Available during shortage	Primary pathway during shortage
Status after Oct 2, 2024	Continues for individualized prescriptions	Cannot compound tirzepatide

Most of the high-volume compounded tirzepatide that drove the 2022-2024 telehealth wave came through 503B facilities. Those facilities cannot legally produce tirzepatide now that the shortage is resolved. FormBlends and similar platforms that continue offering compounded tirzepatide do so through 503A patient-specific prescriptions, which is a different legal pathway with different requirements.

What ended (and what survived)

Three things ended on October 2, 2024:

• 503B outsourcing facility production of tirzepatide for office stock
• 503A compounding based on shortage status alone, without individualized clinical justification
• The "any patient can get compounded tirzepatide because it's on the shortage list" pathway that some telehealth platforms had been using

Three things survived:

• 503A patient-specific compounding when a prescriber documents an individualized clinical reason
• The underlying Section 503A federal statute, which has existed since the Food and Drug Administration Modernization Act of 1997
• State pharmacy law that governs the day-to-day operation of 503A compounding pharmacies

The survival of 503A patient-specific compounding is not a loophole. It is the original framework Congress set up to address legitimate clinical situations where commercial drug products do not fit individual patient needs. Allergen sensitivity to inactive ingredients, dose individualization, and special formulation requirements were the original rationale for the 503A pathway, and they predate GLP-1 medications by decades.

The Outsourcing Facilities Association lawsuit and the March 2025 ruling

The Outsourcing Facilities Association (OFA) filed suit in the U.S. District Court for the Northern District of Texas in October 2024, challenging the FDA's determination that the tirzepatide shortage was resolved. The trade group argued that the FDA had acted arbitrarily and that real-world supply did not match the agency's data.

On March 5, 2025, the court issued a ruling in favor of the FDA. The judge found that the agency had conducted an adequate review of supply data and that Eli Lilly's manufacturing capacity supported the resolution determination. The OFA's request for a preliminary injunction was denied.

The ruling foreclosed the 503B legal pathway for tirzepatide compounding. It did not address 503A patient-specific compounding, which operates under different legal authority and was not challenged in the lawsuit.

What "individualized clinical reason" actually means

The phrase appears in FDA guidance and state pharmacy regulations. It is not a loophole; it is a documented clinical determination by a licensed prescriber. Common reasons that satisfy the requirement include:

• Allergen sensitivity. Some patients react to inactive ingredients in commercial Zepbound or Mounjaro, including specific preservatives or buffering agents. A compounded formulation can omit the triggering ingredient.
• Dose individualization. Commercial tirzepatide comes in fixed doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg). A patient who cannot tolerate the standard titration steps may need an intermediate dose, such as 1.25 mg or 3.75 mg, which is not commercially available.
• Concentration adjustment. Patients with injection-site reactions sometimes benefit from a different concentration that reduces injection volume. Compounding allows formulation to a different mg-per-mL ratio.
• Preservative-free formulation. Patients with documented sensitivity to common preservatives may need a preservative-free preparation.

What does not satisfy the requirement: cost preference, the patient simply preferring the compounded version, or the compounded version being more convenient. These are legitimate concerns but they are not the clinical justification the 503A pathway requires.

The realistic patient pathway in 2026

The path looks different than it did during the shortage period. Here is what most patients now see at FormBlends and similar platforms:

1. Clinical consultation. A licensed prescriber reviews medical history, weight, comorbidities, and prior medication experience. This includes whether the patient has tried brand Mounjaro or Zepbound.
2. Eligibility determination. The prescriber decides whether the patient is appropriate for tirzepatide therapy at all (BMI criteria, contraindications), and if so, whether brand or compounded is the right path.
3. Compounding justification (if compounded). If the prescriber recommends compounded tirzepatide, the chart documents the specific clinical reason. This is the substantive change from the shortage period.
4. 503A pharmacy fulfillment. A licensed 503A pharmacy fills the patient-specific prescription per USP 797 standards.
5. Ongoing review. The prescriber reviews progress, side effects, and the continued clinical justification for compounded vs brand product.

Patients who do not have a documented clinical reason for compounded tirzepatide are now typically directed to brand Mounjaro or Zepbound. Eli Lilly's LillyDirect platform (launched January 2024) offers direct-pay vials at lower prices than the historical pharmacy markup, narrowing the cost gap that drove much of the original compounded demand.

Costs and access since the change

Pricing has shifted in three ways since October 2024.

First, brand Zepbound retail prices have not changed much, but LillyDirect vial pricing introduced a new mid-tier option. The LillyDirect website currently lists 2.5 mg and 5 mg vials at $349 and $499 per month, respectively, paid directly out of pocket. This is meaningfully lower than pharmacy retail through commercial insurance with high deductibles.

Second, compounded tirzepatide prices through 503A pathways have stabilized in the $200-$500 monthly range, depending on dose and pharmacy. The price floor moved up modestly because 503A patient-specific compounding has higher per-unit costs than 503B batch production.

Third, some compounded providers have introduced ancillary "kit" pricing that bundles tirzepatide with other ingredients (B-12, lipotropic mixes, glycine). FormBlends does not bundle by default; bundling can complicate the regulatory analysis and is not clinically necessary for most patients.

What FormBlends does differently now

The platform's clinical workflow changed substantively in late 2024. Three changes are worth noting:

The intake now includes a structured assessment of whether the patient is appropriate for brand Mounjaro or Zepbound before compounded tirzepatide is considered. Many patients who originally came to FormBlends for cost reasons are now offered brand Zepbound through manufacturer pricing programs, including LillyDirect for self-pay patients.

For patients who proceed with compounded tirzepatide, the prescription record now documents the specific clinical reason in standardized fields that the partner 503A pharmacies require. This is the 503A pathway functioning as Congress intended.

The pharmacy partner network was reviewed and consolidated in early 2025. Some 503B-affiliated facilities were removed from the network. The remaining partners are 503A licensed, USP 797 compliant, and subject to state board oversight in their respective jurisdictions.

The contrary view: should compounded tirzepatide go away entirely?

It is worth steelmanning the position that 503A compounding of tirzepatide should not continue at scale.

The strongest version of the argument: tirzepatide is a complex biologic with a narrow therapeutic window and significant adverse event profile. The clinical trial data that supports its safety and efficacy applies to the Eli Lilly product, not to any compounded version. Variability in compounded formulations, pharmacy quality, and storage conditions creates real risk. The 503A pathway was designed for legacy small-molecule drugs, not modern biologics; applying it to tirzepatide stretches the framework beyond its original intent.

This view has support from professional pharmacy organizations and from Eli Lilly's regulatory affairs team. It also has support from physicians who have seen patients harmed by sourcing tirzepatide from non-licensed channels (which is a different problem from licensed 503A compounding, but the distinction is sometimes lost in clinical practice).

The counter: the 503A pathway is a federal statutory authority, not an FDA-granted privilege. Congress, not the FDA, would need to change it. The framework allows for clinical judgment when the commercial product does not fit individual patient needs, and that judgment is meaningful. Eliminating 503A access would push patients toward non-licensed sources, which carries higher risk than licensed compounding.

Both positions are intellectually serious. The current legal framework reflects Congress's judgment that 503A patient-specific compounding has legitimate clinical value, balanced against the risks. The framework is unlikely to change without legislative action.

Decision framework

If you are currently on compounded tirzepatide: Ask your prescriber whether your chart documents an individualized clinical reason. If yes, your access likely continues. If no, ask about transitioning to brand Mounjaro or Zepbound (potentially through LillyDirect for self-pay).

If you are considering starting tirzepatide: Start with the question of whether you meet clinical criteria at all (BMI 30+ or BMI 27+ with comorbidity for Zepbound; diabetes for Mounjaro). If yes, brand Zepbound or Mounjaro is the default. Compounded tirzepatide is appropriate when an individualized clinical reason exists.

If you are a clinician: Document the specific clinical justification in the prescription record. "Patient prefers compounded" is not adequate. "Patient documented allergen sensitivity to polysorbate 80 in commercial product" is.

If you are a self-pay patient priced out of brand: LillyDirect 2.5 mg and 5 mg vial pricing may be more affordable than you expect. Compare actual pricing before assuming compounded is the only path.

FAQ

Is compounded tirzepatide going away?
Not entirely. The shortage-based pathway ended October 2, 2024. The 503A patient-specific pathway continues for individualized clinical reasons.

When did tirzepatide come off the shortage list?
October 2, 2024.

Can pharmacies still compound tirzepatide?
Yes, 503A pharmacies can compound for individual patients with documented clinical justification.

What is the difference between 503A and 503B?
503A is patient-specific, regulated by state pharmacy boards. 503B is batch production, regulated by the FDA. Tirzepatide 503B compounding ended; 503A continues.

Is it legal to get compounded tirzepatide in 2026?
Yes, through a 503A pharmacy with a valid prescription documenting individualized clinical reason.

Will all compounded GLP-1 medications go away?
No. The 503A pathway is preserved by federal statute.

What clinical reasons justify compounded tirzepatide?
Allergen sensitivity to commercial inactive ingredients, dose individualization, concentration adjustment, preservative-free formulation.

Does FormBlends still offer compounded tirzepatide?
Yes, through 503A pharmacy partners for patients with documented clinical justification.

What happens if I'm currently on compounded tirzepatide?
Discuss with your prescriber whether continued use is clinically justified or whether a transition to brand product makes sense.

Is compounded tirzepatide the same as Zepbound?
Same active ingredient; different finished product. Not FDA-approved, not regulatorily equivalent.

Sources

1. FDA Drug Shortage List update, October 2, 2024, resolving tirzepatide shortage
2. FDA Guidance, "Compounding and the FDA: Questions and Answers," current as of 2025
3. Federal Food, Drug, and Cosmetic Act, Sections 503A and 503B, 21 U.S.C. § 353a-b
4. Food and Drug Administration Modernization Act of 1997 (Pub. L. 105-115)
5. Outsourcing Facilities Association v. FDA, U.S. District Court Northern District of Texas, ruling March 5, 2025
6. Jastreboff AM et al., "Tirzepatide Once Weekly for the Treatment of Obesity," New England Journal of Medicine, July 2022 (SURMOUNT-1)
7. USP General Chapter 797, Pharmaceutical Compounding - Sterile Preparations
8. USP General Chapter 795, Pharmaceutical Compounding - Nonsterile Preparations
9. Eli Lilly LillyDirect platform announcement, January 4, 2024
10. FDA Drug Safety Communication on compounded GLP-1 medications, 2024
11. Endocrine Society Clinical Practice Guideline on Obesity, 2023
12. National Association of Boards of Pharmacy, Model State Pharmacy Act and Model Rules, 2024 edition
13. Eli Lilly Q3 2024 manufacturing capacity update, investor relations

Footer disclaimers

Platform Disclaimer. FormBlends is a telehealth platform connecting patients with licensed clinicians and 503A compounding pharmacies. We do not practice medicine, dispense advice, or replace the prescriber-patient relationship. Eligibility, prescribing, and pharmacy fulfillment are independent clinical decisions.

Compounded Medication Notice. Compounded tirzepatide is prepared by a licensed pharmacy for an individual patient based on a valid prescription. It is not FDA-approved. It is not bioequivalent or interchangeable with brand-name Mounjaro or Zepbound in any regulatory sense. Clinical trial efficacy and safety data for tirzepatide apply to the Eli Lilly product specifically.

Results Disclaimer. Weight outcomes vary individually. Trial data summarized here describes group averages and does not predict your specific result. Plateau, regain after discontinuation, and adverse events all occur in real-world use.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. LillyDirect is a service mark of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly.